Subject(s)
Lupus Erythematosus, Systemic/complications , Opportunistic Infections/complications , Toxoplasma/isolation & purification , Toxoplasmosis, Cerebral/complications , Adult , Animals , Anti-Infective Agents/therapeutic use , Antibodies, Protozoan/blood , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/pathology , Drug Combinations , Female , Humans , Immunocompromised Host , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/pathology , Opportunistic Infections/drug therapy , Opportunistic Infections/pathology , Prednisolone/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Sulfamonomethoxine/therapeutic use , Tomography, X-Ray Computed , Toxoplasma/immunology , Toxoplasmosis, Cerebral/drug therapy , Toxoplasmosis, Cerebral/pathology , Treatment OutcomeSubject(s)
Lymphadenitis/parasitology , Toxoplasmosis , Anti-Infective Agents/therapeutic use , Antiprotozoal Agents/therapeutic use , Humans , Lymphadenitis/drug therapy , Pyrimethamine/therapeutic use , Spiramycin/analogs & derivatives , Spiramycin/therapeutic use , Sulfadiazine/therapeutic use , Sulfamonomethoxine/therapeutic useABSTRACT
Feedlot calves naturally infected with Eimeria spp. were medicated by a combination of sulfamonomethoxine and ormetoprim (Ektecin). Calves, less than one year old and positive for coccidiosis, were administered with Ektecin (5, 10 and 20 ml/100 kg of body weight/day) and Daimeton (100% sulfamonomethoxine: 5 g/100 kg of body weight/day) for five days. No diarrhea were found on and after 3 days of medication in all the groups, and no oocysts were detected on and after day 5, 2, 1 or 3 from calves of the respective medicated groups. In samples from a group of calves administered with lowest dose of Ektecin, eimerian oocysts of 4 species were detected on day 0, and additionally 3 species (totally 7 species) were found on day 3 of medication.
Subject(s)
Anti-Infective Agents/therapeutic use , Cattle Diseases/drug therapy , Coccidiosis/veterinary , Eimeria/isolation & purification , Pyrimidines/therapeutic use , Sulfamonomethoxine/therapeutic use , Animals , Cattle , Coccidiosis/drug therapy , Dose-Response Relationship, Drug , Drug Therapy, CombinationABSTRACT
The in vitro studies revealed a number of promising drugs including gentamicin, doxycycline and minocycline for the treatment of malleus. The malleus causative agent was found to be highly susceptible to sulfamonomethoxine and biseptol as well as to imipenem and ofloxacin. Cephalosporins were less active but in the therapeutic concentrations they inhibited the growth of Pseudomonas mallei. In the treatment of golden hamsters infected subcutaneously by P. mallei ofloxacin proved to be the most active drug, then followed biseptol, doxycycline and minocycline. None of the tested drugs cured the animals infected aerogenically by 160 LD50 of P. malleus. When the infective dose was lower (16 LD50) only doxycycline provided a 70-percent protection of the animals.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Glanders/drug therapy , Animals , Cephalosporins/therapeutic use , Cricetinae , Doxycycline/therapeutic use , Gentamicins/therapeutic use , Imipenem/therapeutic use , Mesocricetus , Minocycline/therapeutic use , Ofloxacin/therapeutic use , Sulfamonomethoxine/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic useABSTRACT
Derivatives of diaminopyrimidine as potentiators of the effect of the derivatives of sulfanilamide and other antibacterial drugs are discussed. Experimental data on sulfation, a new combined preparation, based on sulfamonomethoxine (a sulfanilamide derivative) and trimethoprim (a diaminopyrimidine derivative) are presented. Brief clinical characteristics of sulfation, its administration routes, doses, dosage advantages and better tolerance as compared to co-trimethoxazole+ (biseptol) are described.
Subject(s)
Bacterial Infections/drug therapy , Pyrimidines/administration & dosage , Sulfamonomethoxine/administration & dosage , Sulfamonomethoxine/therapeutic use , Sulfanilamides/administration & dosage , Sulfanilamides/therapeutic use , Trimethoprim/administration & dosage , Trimethoprim/therapeutic use , Animals , Anti-Infective Agents , Chemical Phenomena , Chemistry , Clinical Trials as Topic , Drug Combinations/therapeutic use , Drug Evaluation, Preclinical , Drug Therapy, Combination , Humans , Mice , SulfanilamideABSTRACT
Nearly 80% of 87 cattle suffering for the first time from pododermatitis circumspecta were cured by each of the three drugs under test. Sixty and 73% of those cured by sulphamonomethoxine and penicillin, respectively, and 29% of those cured by the tarantula poison (Theranekron), showed relapses within 6 months. Of the 92 cattle with previous records of pododermatitis circumspecta, sulphamonomethoxine cured 44%, penicillin 73% and Theranekron 32%. Of the latter three groups 72-80% showed relapses within the subsequent 6 months. The results of surgical treatments were, possibly, improved by the prior administration of Theranekron. In addition, in a pilot trial, the demarcation of a gangreneous udder half of a goat suffering from blue-bag, appeared to be accelerated by the parenteral administration of Theranekron.
Subject(s)
Arthropod Venoms/therapeutic use , Cattle Diseases/drug therapy , Foot Dermatoses/veterinary , Hoof and Claw , Penicillins/therapeutic use , Spider Venoms/therapeutic use , Sulfamonomethoxine/therapeutic use , Sulfanilamides/therapeutic use , Animals , Cattle , Clinical Trials as Topic , Female , Foot Dermatoses/drug therapyABSTRACT
The preventive effect of sulfamonomethoxine (Smm) and ormetoprim (Omp) medicated in combination against leucocytozoon infection in chickens was tested in field trials. In trial 1, medication was given continuously throughout the experimental period. In trial 2, medication was given for seven days and no medication was given for the next seven days; then this schedule for the medication was repeated throughout the experimental period. In trial 1, almost complete prevention was obtained when Smm and Omp were added to the feed at the level of 12 ppm and 14 ppm, respectively, or at the level of 15 ppm and 5 ppm, respectively. Only a partial effect was obtained, however, when these drugs were used at the level of 9 ppm and 3 ppm, respectively. In trial 2, a nearly complete effect was obtained when Smm and Omp were added to the feed at the level of 18 ppm and 6 ppm respectively, but we found no effect when these drugs were used at the level of 15 ppm and 5 ppm, respectively. There were no significant differences among the groups as to the weight gain.
Subject(s)
Chickens , Poultry Diseases/drug therapy , Protozoan Infections, Animal , Pyrimidines/therapeutic use , Sulfamonomethoxine/therapeutic use , Sulfanilamides/therapeutic use , Animals , Antibodies/analysis , Apicomplexa , Poultry Diseases/immunology , Poultry Diseases/parasitology , Protozoan Infections/immunology , Protozoan Infections/parasitologyABSTRACT
In experiments in vitro dioxidineeee was highly effective as regards all the test cultures of NAG-vibrios. The MTC ranged within 1 to 62 micrograms/ml. Bactericidal action of the drug became manifest at concentrations from 4 to 250 micrograms/ml. The derivatives of di-N-oxide quinoxaline, dioxidin and quinoxidine exerted a chemotherapeutic effect and sterilizing action in experimental NAG-infection. The action of the drugs was potentiated upon combined use with lysozyme. As far as depo-sulfanilamides are concerned, sulfalenee was little active, while sulfamonomethoxine ineffective in experimental NAG-infection.